[go: up one dir, main page]

EP1919549A1 - Systeme transcorneen permettant de delivrer une substance active medicamenteuse - Google Patents

Systeme transcorneen permettant de delivrer une substance active medicamenteuse

Info

Publication number
EP1919549A1
EP1919549A1 EP06792966A EP06792966A EP1919549A1 EP 1919549 A1 EP1919549 A1 EP 1919549A1 EP 06792966 A EP06792966 A EP 06792966A EP 06792966 A EP06792966 A EP 06792966A EP 1919549 A1 EP1919549 A1 EP 1919549A1
Authority
EP
European Patent Office
Prior art keywords
amino
phenyl
quinazoline
chloro
matrix material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06792966A
Other languages
German (de)
English (en)
Inventor
Marc Egen
Maria Piccini
Johannes Geser
Christian Feiertag
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of EP1919549A1 publication Critical patent/EP1919549A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046—Solid microneedles

Definitions

  • the invention relates to a transcorneal drug delivery system which is present in a matrix material forming a base plate, wherein the base plate for penetration of the stratum corneum of the skin is associated with a plurality of protrusions, and a method of preparation.
  • EP 0 840 634 B1 discloses a transcorneal drug delivery system comprising a drug reservoir and a micro spiked device with capillary or microcutaneous apertures having a length of at least 10 ⁇ m and communicating with the drug via a fluid conducting compound - Servoir are connected, that an active transport of the drug from the reservoir through the micro spines or along the micro-cutting is possible.
  • an integrated pump with electronic control is provided for active release of the active substance from the reservoir through the micro spines or along the micro-cutting. Due to the integrated pump with electronic control, this system has a complex and expensive construction.
  • US Pat. No. 3,964,482 discloses a transcorneal drug delivery system comprising a drug reservoir in a base plate provided with needle-like elevations for penetrating the skin.
  • the active ingredient diffuses from the active substance reservoir through the elevations and enters the skin, the active substance traversing a relatively long path, determined by the thickness of the base plate and the length of the elevations.
  • the relatively large time delay, the so-called lag-time, until the drug his Effect as intended which is usually up to ten hours.
  • transdermal system This is a system of needles made of a biodegradable polymer and applied to a plate. This plate has depressions in which the drug is located and can penetrate with the help of the needles into the skin.
  • the active substance within the meaning of the invention may be a composition of different substances, in particular pharmaceutically active substances, or a placebo.
  • the object is achieved in the system in that the elevations consist of the matrix material and include the active ingredient.
  • the active substance present in the elevations comes directly into the layer of the skin below the stratum corneum, in which it can develop its effect, whereby the lag-time until onset of action over conventional systems is significantly shortened.
  • the active ingredient is present not only within the elevations, but also on their outer surfaces, and its transport due to the permeation via fluids of the skin is rapid.
  • the elevations are preferably formed integrally with the base plate and pyramid-shaped.
  • the pyramidal shape also has a penetration of the stratum corneum with a low force result.
  • the bumps are chosen in length so that they do not penetrate into the nerve-bearing tissue, thereby avoiding pain for the user of the system.
  • the nerve-bearing tissue is about 200-500 microns below the Skin surface, which varies depending on the body region.
  • the active ingredient is present in solid form, as a solution or gel in the matrix material.
  • Suitable agents are, for example, agents for heart disease - such.
  • B. thrombolytic substances for examplereteplase or tenecteplase
  • Agents for stroke treatment - e.g. Dipyridamole, if necessary. in combination with other agents, such.
  • B. acetylsalicylic acid antiviral agents, such as B. protease inhibitors, for example tipranavir; antidepressants; Inflammatory insufficiency - such. Meloxicam; Agents for the treatment of respiratory diseases, such. B. tiotropium, if necessary.
  • Painkillers such as Morphine, naltrexone, fentanyl, oxymorphone
  • Anti-Parkinson agents - such as L-Dopa, pramipexole
  • Cardiovascular nitroglycerin, antihypertensive agents - such as. B. Telmisartan, if necessary. in combination with other agents and vasodilating diseases such as clonidine, nifidepine, verapamil, diltiazam; Anticoagulants, such as heparin, hirudin
  • Long-term therapy for cancer and immune diseases - such as B. nevirapine for the treatment of autoimmune diseases; Long-term treatment for addiction therapy; peptides; ACE inhibitors; Neurokinin antagonists; Hormones, such as estradiol.
  • W is a pharmacologically active agent and (for example) selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HIV antihistamines, P AF Antagonists and PB kinase inhibitors.
  • W represents a betamimetics combined with an anticholinergic, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists,
  • W represents an anticholinergic agent combined with a betamimetics, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists
  • W represents a corticosteroid combined with a PDE4 inhibitor, EGFR inhibitor or LTD4 antagonist
  • W represents a PDE4 inhibitor combined with an EGFR inhibitor or LTD4 antagonist - W represents an EGFR inhibitor combined with a LTD4 antagonist.
  • Preferred betamimetics for this purpose are compounds selected from the group consisting of albuterol, arformoterol, bambuterol, bitolertrol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharines, isoprenaline, levosalbutamol, mabuterol, meluadrine , Metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmefamol, salemetole, soterenol, sulphoneterol, terbutaline, tiaramide, toluubuterol, zinterol, CHF-1035, HOKU-81, KUL-1248 and
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,
  • Preferred anticholinergic compounds are compounds which are selected from the group consisting of tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt Trospium salts, preferably the chloride salt, tolterodine.
  • the cations are the pharmacologically active ingredients.
  • the abovementioned salts may preferably contain chloride, bromide, iodine, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate , Succinate, benzoate or p-toluenesulfonate, with chloride, bromide, iodide, sulfate, methanesulfonate or p-toluenesulfonate being preferred as counterions.
  • the chlorides, bromides, iodides and methanesulfonates are particularly preferred.
  • anticholinergics are selected from the salts of the formula AC-I
  • X ⁇ is a single negatively charged anion, preferably an anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-Toluene sulfonate, preferably a singly negatively charged anion, more preferably an anion selected from the group consisting of fluoride, chloride, bromide, methanesulfonate and p-toluenesulfonate, most preferably bromide, optionally in the form of their racemates, enantiomers or hydrates.
  • anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate
  • R is either methyl or ethyl and in which X ⁇ may have the abovementioned meanings.
  • the compound of the formula AC-2 also in the form of the free base AC-2-base.
  • Preferred corticosteroids are compounds selected from the group consisting of beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone , RPR-106541, NS-126, ST-26 and
  • Examples of possible salts and derivatives of the steroids may be: alkali metal salts, such as sodium or potassium salts, Sulfobenzoa- te, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
  • compounds are preferably used which are selected from the group consisting of enprofylline, theophylline, roflumilast, A-riflo (cilomilast), tof ⁇ milast, pumafentrin, lirimilast, arofylline, atizoram, D-4418, bovine 198004, BY343, CP-325,366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS
  • the acid addition salts of the betamimetics are preferably selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrogen phosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate,
  • Hydro fumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate are Hydro fumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Preferred LTD4 antagonists here are compounds which are selected from the group consisting of montelukast, pranlukast, zafirlukast,
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,
  • Examples of salts or derivatives whose formation the LTD4 antagonists are capable of are: alkali metal salts, such as sodium or potassium salts, alkaline earth salts, sulfobenzoates, phosphates, isonicoates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or also furoate.
  • the EGFR inhibitors used are preferably compounds selected from the group consisting of cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and - 4 - [(3-chloro-4-fluorophenyl) amino] -6- ⁇ [4- (morpholin-4-yl) -1-oxo-2-butene-1-yl-amino ⁇ -7-cyclopropyl-methoxy-quinazoline
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,
  • Preferred dopamine agonists are compounds selected from the group consisting of bromocriptine, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexole, roxindole, ropinirole, talipexole, terguride and viozan, optionally in the form of their racemates , Enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • the acid addition salts of the betamimetics are preferably selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate,
  • the compound may be derived from the group of derivatives of ergot alkaloids, the triptans, the CGRP inhibitors, the phosphodiesterase V inhibitors, optionally in the form of their racemates, enantiomers or diastereomers, optionally in the form of their pharmacologically acceptable acid addition salts, their solvates and / or hydrates.
  • the matrix material is a polymer or a salt.
  • Such polymers or salts are suitable with which, on the one hand, a precise metering of the active substance into the skin is possible and, on the other hand, have such material properties, such as hardness and elasticity, that the elevations penetrate the stratum corneum.
  • the polymer is biodegradable.
  • the biodegradable polymer can be selected from a group consisting of poly-a-hydroxyester, poly-b-hydroxyester, polyanhydrides, polycyanoacrylates, cellulose, cellulose esters, polypeptides (polyaspartic acid), polylactones, polyglycols.
  • Biodegradable polymers have the advantage that any remaining particles in the skin are degraded.
  • the polymer is a copolymer of lactic and glycolic acid.
  • Such copolymers also serve as raw materials for the preparation of active ingredient capsules for the controlled release of pharmaceutical active substances.
  • a poly (L-lactide-co-D, L-lactide) 70:30 and especially a 50:50 poly (D, L-lactide-co-glycolide) is suitable as a matrix material.
  • the matrix material and the elevations advantageously have channels in which the active ingredient is present.
  • the channels are formed due to the mixing ratio of the matrix material and the drug due to local accumulations of the drug, which are favored by the very different molecular weights of the matrix material and the active ingredient. about These channels penetrate not only the existing in the surveys active ingredient in the skin, but also passes into the base plate present drug through the channels there, if already the drug was transported from the surveys into the skin.
  • the length of the elevations or the microneedles is expediently dimensioned in such a way that they penetrate into the epidermis of the skin.
  • the base plate is coated with a protective film.
  • an adhesive surface for attachment to the skin is provided. Suitable adhesive surfaces and adhesives are well known to those skilled in the art.
  • the object is achieved in the process for producing a transcorneal system for delivering a drug substance with a polymeric matrix material in that the powdery matrix material is mixed with the active ingredient, melted in an extruder and the composite material produced is shaped in a shaping process such, that a base plate with elevations for penetration of the Straumum corneum of the skin is present.
  • a method which allows the production of a previously explained transcorneal system in large numbers and thus cost.
  • the individual processing parameters such as temperature and pressure, are dependent on the polymeric matrix material and the active ingredient and are chosen such that material or active substance damage is ruled out.
  • the volume percentage of the matrix material is set to the composite material less than or equal to the volume percentage of the active ingredient.
  • the ratio of the matrix material to the active ingredient is For example, 20% by volume / 80% by volume, preferably 40% by volume / 60% by volume or 50% by volume / 50% by volume. If only small amounts of active ingredient are to be released, it goes without saying that the volume percentage of the matrix material on the composite material can be greater than the volume percentage of the active ingredient. The ratio is therefore arbitrary.
  • the active ingredient in solid form is micronized prior to mixing with the melt.
  • FIG. 1 is a schematic partial representation of a top view of a transcorneal system according to the invention
  • FIG. 2 is a sectional view of the system according to the line H-II of FIG. 1,
  • FIG. 3 is an enlarged view of a detail III of FIG. 2,
  • the transcorneal system for delivering a drug substance comprises a base plate 1 made of a polymeric matrix material in which the active ingredient is present, wherein the base plate 1 is integrally connected to a plurality of pyramidal elevations 4 for penetration into the stratum corneum 2 of the skin 3 , which consist of the matrix material and also have the active ingredient.
  • the ratio of the height to the base of the needle corresponds to about 2 parts height to 1 part base side. Per cm 2 of the base plate about 370 surveys are provided.
  • the polymer of the base plate 1 and the bumps 4 is a biodegradable copolymer of lactic and glycolic acid, which is mixed with about 60% by volume of the micronized solid active ingredient and melted in an extruder.
  • the contour of the system is made.
  • the active ingredient separates out in phases, which leads to the formation of channels within the matrix material in which the active ingredient is present and which substantially promote permeation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un système transcornéen permettant de délivrer une substance active médicamenteuse présente dans une matière matricielle formant une plaque de base (1). Cette plaque de base (1) est reliée à une pluralité de parties en saillie (4) afin de pénétrer la couche cornée de la peau. Ces parties en saillie (4) sont constituées de la matière matricielle et présentent la substance active.
EP06792966A 2005-08-24 2006-08-23 Systeme transcorneen permettant de delivrer une substance active medicamenteuse Withdrawn EP1919549A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005040251A DE102005040251A1 (de) 2005-08-24 2005-08-24 Transcorneales System zur Abgabe eines Arzneimittel-Wirkstoffes
PCT/EP2006/065585 WO2007023167A1 (fr) 2005-08-24 2006-08-23 Systeme transcorneen permettant de delivrer une substance active medicamenteuse

Publications (1)

Publication Number Publication Date
EP1919549A1 true EP1919549A1 (fr) 2008-05-14

Family

ID=37188806

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06792966A Withdrawn EP1919549A1 (fr) 2005-08-24 2006-08-23 Systeme transcorneen permettant de delivrer une substance active medicamenteuse

Country Status (6)

Country Link
US (1) US20090011026A1 (fr)
EP (1) EP1919549A1 (fr)
JP (1) JP5198268B2 (fr)
CA (1) CA2619041C (fr)
DE (1) DE102005040251A1 (fr)
WO (1) WO2007023167A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8136034B2 (en) * 2007-12-18 2012-03-13 Aaron Stanton System and method for analyzing and categorizing text
FR2973237A1 (fr) 2011-03-31 2012-10-05 Oreal Procede de traitement cosmetique fractionne utilisant un laser ou des micro-aiguilles
CN106166326A (zh) * 2016-08-19 2016-11-30 王子元 一种非介入导入方法
FR3122826A1 (fr) 2021-05-12 2022-11-18 L'oreal Procedes et compositions pour l’amelioration de la peau
FR3124952A1 (fr) 2021-07-09 2023-01-13 L'oreal Procédés et compositions pour l’amélioration de la peau

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US4919939A (en) * 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
US5230897A (en) * 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
DE19525607A1 (de) * 1995-07-14 1997-01-16 Boehringer Ingelheim Kg Transcorneales Arzneimittelfreigabesystem
JP2002517300A (ja) * 1998-06-10 2002-06-18 ジョージア テック リサーチ コーポレイション 微小針デバイスおよび製造方法ならびにそれらの使用
US7226469B2 (en) * 1999-02-02 2007-06-05 Arthrex, Inc. Insert molded suture anchor
US6689103B1 (en) * 1999-05-07 2004-02-10 Scimed Life System, Inc. Injection array apparatus and method
US6256533B1 (en) * 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
US6821281B2 (en) * 2000-10-16 2004-11-23 The Procter & Gamble Company Microstructures for treating and conditioning skin
EP1345646A2 (fr) * 2000-12-14 2003-09-24 Georgia Tech Research Corporation Appareils a microaiguilles et fabrication
AU2003206382B2 (en) * 2002-01-03 2008-01-24 Smithkline Beecham Corporation Novel pharmaceutical dosage forms and method for producing same
US7318944B2 (en) * 2003-08-07 2008-01-15 Medtronic Vascular, Inc. Extrusion process for coating stents
JP2007503268A (ja) * 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
EP1706171A1 (fr) * 2003-12-29 2006-10-04 3M Innovative Properties Company Dispositifs medicaux et kits comprenant ces dispositifs
US20060003008A1 (en) * 2003-12-30 2006-01-05 Gibson John W Polymeric devices for controlled release of active agents
WO2005082593A1 (fr) * 2004-02-17 2005-09-09 Avery Dennison Corporation Procede de fabrication de micro-aiguilles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007023167A1 *

Also Published As

Publication number Publication date
JP5198268B2 (ja) 2013-05-15
DE102005040251A1 (de) 2007-03-01
CA2619041C (fr) 2014-07-29
US20090011026A1 (en) 2009-01-08
JP2009506013A (ja) 2009-02-12
WO2007023167A1 (fr) 2007-03-01
CA2619041A1 (fr) 2007-03-01

Similar Documents

Publication Publication Date Title
EP2004263B1 (fr) Dispositif d'émission de médicaments et magasins à médicaments
EP2007458B1 (fr) Inhalateur
EP1948274B1 (fr) Aiguille pour percer des capsules de poudre pour l'inhalation
EP2656867B1 (fr) Embouchure pour un inhalateur
EP2007457A1 (fr) Inhalateur
WO2009016238A2 (fr) Inhalateur
EP1942968A1 (fr) Inhalateur avec embout ayant une fonction de protection microbiologique
EP2370053A1 (fr) Nouveaux médicaments sous forme de poudre cristalline à inhaler
EP2001601B1 (fr) Aérosols de dosage pour l'administration de préparations pharmaceutiques
WO2009013243A1 (fr) Nouvel agent pharmaceutique poudreux contenant du tiotropium et du salmétérol ainsi que du lactose en tant qu'agent auxiliaire
EP2299990A1 (fr) Nouvelles particules à principe actif incorporé pour inhalation
EP1919549A1 (fr) Systeme transcorneen permettant de delivrer une substance active medicamenteuse
DE102006044755A1 (de) Inhalator
WO2007118341A1 (fr) Dispositif d'émission de médicaments
DE102007036412A1 (de) Prüfvorrichtung
WO2009098083A1 (fr) Procédé et dispositif pour remplir des gélules
WO2009013190A1 (fr) Dispositif et procédé de détermination de la teneur en humidité d'une matière d'emballage
WO2009150120A1 (fr) Nouvelles émulsions pour la préparation de médicaments
EP2001536A1 (fr) Emballage pour inhalateur de poudre multidose avec proprietes optimisees de purge
DE102007034156A1 (de) Vorrichtung und Verfahren zur Bestimmung des Feuchtegehalts eines Verpackungsmaterials
DE102007052871A1 (de) Kapsel zur Aufnahme von pharmazeutischen Wirkstoffformulierungen
DE102007036413A1 (de) Vorrichtung und Verfahren zur Bestimmung des Feuchtegehalts eines Verpackungsmaterials
EP2198972A1 (fr) Réservoir et gicleur

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080325

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20131118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161005